CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.
作者信息
Leong Sarah, Inglott Sarah, Papaleonidopoulou Foteini, Orfinada Karen, Ancliff Philip, Bartram Jack, Carpenter Ben, Fielding Adele K, Ghorashian Sara, Grandage Victoria, Gupta Rajeev, Hough Rachael, Khwaja Asim, Pavasovic Vesna, Rao Anupama, Samarasinghe Sujith, Vora Ajay, Mansour Marc R, O'Connor David
机构信息
Department of Haematology, University College London Hospital, London, United Kingdom.
Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.
出版信息
Blood Adv. 2020 Oct 13;4(19):4665-4668. doi: 10.1182/bloodadvances.2020002502.
Abstract
摘要
相似文献
1
CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.
Blood Adv. 2020 Oct 13;4(19):4665-4668. doi: 10.1182/bloodadvances.2020002502.
2
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000630.
3
Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Expert Opin Investig Drugs. 2021 Jun;30(6):611-620. doi: 10.1080/13543784.2021.1916466. Epub 2021 May 4.
4
Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005333.
5
Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Indian J Pediatr. 2024 Feb;91(2):168-175. doi: 10.1007/s12098-023-04745-z. Epub 2023 Aug 29.
6
Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Hematol Oncol Clin North Am. 2009 Oct;23(5):1121-35, vii-viii. doi: 10.1016/j.hoc.2009.07.008.
7
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Blood. 2019 May 23;133(21):2291-2304. doi: 10.1182/blood-2018-10-882944. Epub 2019 Feb 22.
8
Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
Am J Hematol. 2023 Dec;98(12):1898-1908. doi: 10.1002/ajh.27094. Epub 2023 Sep 23.
9
Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from China.
Asia Pac J Clin Oncol. 2022 Apr;18(2):e87-e95. doi: 10.1111/ajco.13562. Epub 2021 Jun 23.
10
Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Cancer Lett. 2018 May 28;422:107-117. doi: 10.1016/j.canlet.2018.02.033. Epub 2018 Feb 23.
引用本文的文献
1
Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.
Leukemia. 2025 Aug 14. doi: 10.1038/s41375-025-02723-2.
2
CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.
J Hematol Oncol. 2025 Jul 1;18(1):69. doi: 10.1186/s13045-025-01715-0.
3
CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
Blood Adv. 2025 Feb 25;9(4):913-923. doi: 10.1182/bloodadvances.2023012263.
4
Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party.
Bone Marrow Transplant. 2024 Sep;59(9):1239-1246. doi: 10.1038/s41409-024-02300-8. Epub 2024 Jun 4.
5
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Ann Hematol. 2023 Aug;102(8):2001-2013. doi: 10.1007/s00277-023-05286-3. Epub 2023 May 25.
6
Current state of CAR-T therapy for T-cell malignancies.
Ther Adv Hematol. 2022 Dec 26;13:20406207221143025. doi: 10.1177/20406207221143025. eCollection 2022.
7
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Front Immunol. 2022 Aug 16;13:949140. doi: 10.3389/fimmu.2022.949140. eCollection 2022.
8
SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):718-725. doi: 10.1016/j.clml.2022.07.010. Epub 2022 Jul 20.
9
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.
Cancers (Basel). 2022 Jun 11;14(12):2886. doi: 10.3390/cancers14122886.
10
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.
Haematologica. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851.
本文引用的文献
1
Harnessing immunotherapy for pediatric T-cell malignancies.
Expert Rev Clin Immunol. 2020 Apr;16(4):361-371. doi: 10.1080/1744666X.2020.1732819. Epub 2020 Feb 27.
2
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Blood. 2019 May 23;133(21):2291-2304. doi: 10.1182/blood-2018-10-882944. Epub 2019 Feb 22.
3
A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.
Am J Cancer Res. 2019 Jan 1;9(1):64-78. eCollection 2019.
4
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.
Front Immunol. 2018 Nov 28;9:2722. doi: 10.3389/fimmu.2018.02722. eCollection 2018.
5
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.
Leukemia. 2018 Nov;32(11):2307-2315. doi: 10.1038/s41375-018-0285-8. Epub 2018 Oct 12.
6
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.
Haematologica. 2018 Oct;103(10):e489-e490. doi: 10.3324/haematol.2018.197640. Epub 2018 Jun 28.
7
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
Bone Marrow Transplant. 2018 Nov;53(11):1487-1489. doi: 10.1038/s41409-018-0222-5. Epub 2018 Jun 8.
8
An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Leukemia. 2018 Sep;32(9):1970-1983. doi: 10.1038/s41375-018-0065-5. Epub 2018 Feb 20.
9
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
10
Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.
Blood Adv. 2017 Nov 21;1(25):2348-2360. doi: 10.1182/bloodadvances.2017009928. eCollection 2017 Nov 28.
Zotero 插件